QR Code

The efficacy of tixagevimab/cilgavimab (Evusheld) in prophylaxis and treatment of COVID-19 in immunocompromised patients: a systematic review and meta-analysis

Abstract Background During the COVID-19 pandemic, some populations, including immunocompromised patients, could not tolerate COVID-19 vaccination or had low responses. Evusheld is a combined neutralizing monoclonal antibody containing tixagevimab and cilgavimab. The World Health Organization (WHO) h...

Full description

Saved in:
Main Authors: Shaymaa Glhoom, Aya Fergany, Dina El-Araby, Asmaa A. Abdelkhalek, Asmaa Gomaa, Eman O. Zayed, Mohamed Abd-ElGwad
Format: Artigo
Language:Inglês
Published: BMC 2024-01-01
Series:European Journal of Medical Research
Subjects:
Cilgavimab
Tixagevimab
Evusheld
AZD7442
COVID-19
Online Access:https://doi.org/10.1186/s40001-023-01549-x
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items